Nachrichten zur Heron Therapeutics Inc. Aktie

Heron Therapeutics: Approved Therapy With Blockbuster Potential But Meager Revenues

…

Heron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call Transcript

…

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer

SOUTH SAN FRANCISCO, Calif, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an…

Heron Therapeutics, Inc., (HRTX) Q2 2024 Earnings Call Transcript

…

Heron Therapeutics, Inc. 2024 Q2 - Results - Earnings Call Presentation

…

Heron Therapeutics: Opioid-Free Surgical Pain Relief Maven With Low Cash Reserves

…

CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236

Company continuing IND-enabling activities in preparation for submission of Investigational New Drug Application to FDA…

Earnings call: Heron Therapeutics reports revenue growth in Q1 2024 By Investing.com

Earnings call: Heron Therapeutics reports revenue growth in Q1 2024…

Heron Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation

…

Heron Therapeutics, Inc. (HRTX) Q1 2024 Earnings Call Transcript

…

Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain

…

Heron Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation

…

Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript

…

Heron Therapeutics rises on securing label expansion for pain therapy

…

Upcoming FDA Decision: Heron Therapeutics ZYNRELEF SNDA

…

Merck close to acquiring cancer specialist Harpoon Therapeutics

Merck & Co Inc (NYSE:MRK) is close to acquiring Harpoon Therapeutics Inc, a cancer drug developer, for about $700 million to…

Heron Therapeutics partners with CrossLink for ZYNRELEF sales By Investing.com

Heron Therapeutics partners with CrossLink for ZYNRELEF sales…

Why Heron Therapeutics Is A Compelling Buy Into 2024

…

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Spero Therapeutics Inc. (NASDAQ: SPRO)

NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that it has commenced an investigation…

Heron Therapeutics, Inc. (HRTX) Q3 2023 Earnings Call Transcript

…

Heron Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation

…

Heron Therapeutics (HRTX) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter…

Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates

Company is well capitalized after signing $50 million working capital credit facility and recent $30 million equity raise Favorable outcome…

Heron Therapeutics Q2 2023 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Heron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023

SAN DIEGO, Aug. 7, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the…

Heron Therapeutics Shares Rise 6.2% After Restructuring, Cost Reduction Plan

Heron Therapeutics Shares Rise 6.2% After Restructuring, Cost Reduction Plan...…

Heron Therapeutics rises on layoffs, ~$30M private placement financing

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Heron Therapeutics Appoints Ira Duarte as Finance Chief

Heron Therapeutics Appoints Ira Duarte as Finance Chief...…

Form 8-K HERON THERAPEUTICS, INC. For: Jun 16

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Heron Therapeutics appoints Ira Duarte as CFO

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer

SAN DIEGO, June 23, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the…

Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer

SAN DIEGO, June 12, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the…

Heron Therapeutics Hit 52-Week Low After Wider-Than-Expected 1Q Loss

Heron Therapeutics Hit 52-Week Low After Wider-Than-Expected 1Q Loss...…

Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates

· Net Product Sales for First Quarter of 2023 Grew 26% to $29.6 million, Compared to First Quarter Net Product…

Heron Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

SAN DIEGO, May 4, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the…

Heron Therapeutics President Poyhonen Leaving in Commercial Team Shake-Up >HRTX

Heron Therapeutics President Poyhonen Leaving in Commercial Team Shake-Up >HRTX...…

Heron Therapeutics Announces Commercial Leadership Changes

SAN DIEGO, April 20, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron"), a commercial-stage biotechnology company focused on improving…

Why Heron Therapeutics Stock Has Been on Fire This Week

Wall Street is cheering a change in leadership at the company....…

Why Shares of Heron Therapeutics Jumped Thursday

The stock has been rising since the company appointed a new CEO....…

Heron Therapeutics picks industry veteran as CEO, elects new board chairman

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Heron Therapeutics Chairman, CEO Barry Quart Resigns >HRTX

Heron Therapeutics Chairman, CEO Barry Quart Resigns >HRTX...…

Heron Therapeutics Announces New CEO and Board Chairman

Craig Collard Appointed CEO Adam Morgan Named Chairman of the Board SAN DIEGO, April 3, 2023 /PRNewswire/ -- Heron Therapeutics,…

Form 8-K HERON THERAPEUTICS, INC. For: Mar 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 10-K HERON THERAPEUTICS, INC. For: Dec 31

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Heron Therapeutics Shares Rise Premarket as 4Q Results Top Views >HRTX

Heron Therapeutics Shares Rise Premarket as 4Q Results Top Views >HRTX...…

Heron Therapeutics GAAP EPS of -$0.17 beats by $0.15, revenue of $30.03M beats by $2.79M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K HERON THERAPEUTICS, INC. For: Mar 23

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates

- Annual Net Product Sales Across the Company Grew 25% to $107.7 million in 2022, Compared to Annual Net Product…

Form 8-K HERON THERAPEUTICS, INC. For: Mar 13

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Heron Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 23, 2023

SAN DIEGO, March 10, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the…